AXID AR Drug Patent Profile

Which patents cover Axid Ar, and when can generic versions of Axid Ar launch?

Axid Ar is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in AXID AR is nizatidine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nizatidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Axid Ar

A generic version of AXID AR was approved as nizatidine by EPIC PHARMA LLC on July 5^th, 2002.

Summary for AXID AR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	27
DailyMed Link:	AXID AR at DailyMed

US Patents and Regulatory Information for AXID AR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	AXID AR	nizatidine	TABLET;ORAL	020555-001	May 9, 1996		OTC	Yes	Yes

Expired US Patents for AXID AR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	AXID AR	nizatidine	TABLET;ORAL	020555-001	May 9, 1996

International Patents for AXID AR

See the table below for patents covering AXID AR around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	930107
Spain	505950
Romania	82215	PROCEDEU PENTRU PREPARAREA UNOR DERIVATI DE TIAZOL (PROCESS FOR PREPARING THIAZOLE DERIVATIVES)
Denmark	435181
South Korea	850001795
Ireland	812285

Market Dynamics and Financial Trajectory for AXID AR

Last updated: February 20, 2026

What is AXID AR and what is its current market position?

AXID AR (Aclidinium Bromide) is an inhaled anticholinergic agent approved for chronic obstructive pulmonary disease (COPD). It competes mainly within the long-acting muscarinic antagonist (LAMA) class, with a focus on patients requiring maintenance therapy for airflow obstruction. As a branded product, AXID AR targets a segment characterized by an increasing prevalence of COPD, especially in aging populations across North America and Europe.

Market penetration remains limited compared to leading drugs such as Spiriva (tiotropium) and Seebri (glycopyrrolate). Its distribution is primarily through specialized respiratory pharmacies and hospitals, constraining access to wider patient populations.

How is the global COPD treatment market evolving?

The COPD treatment market is projected to reach USD 37.5 billion by 2027, growing at a CAGR of 4.2% from 2020 (Fortune Business Insights, 2021). The growth drivers include:

• An aging population in developed economies.
• Increasing prevalence of smoking and air pollution.
• Growth in the adoption of combination therapies.

Key regions include North America (dominant market share), Europe, and Asia-Pacific.

What are the key factors influencing AXID AR's market trajectory?

Competitive landscape

• Major competitors: Tiotropium (Spiriva), glycopyrrolate (Seebri), aclidinium bromide (Pressair).
• Market shares: Spiriva holds an estimated 35% of the LAMA market (IQVIA, 2022).
• Differentiators: Limited clinical benefit data, lack of unique delivery features, and price disparities influence market uptake.

Regulatory environment

• Ongoing patent protections for key competitors delay generic entry.
• Regulatory approval for fixed-dose combinations has expanded treatment options but favors established products.
• Price control policies, especially in Europe, impact revenue potential.

Technological advancements

• Development of fixed-dose inhalers combining LAMAs with long-acting beta-agonists (LABAs) enhances treatment adherence.
• Digital health integration in inhalers aids monitoring but is primarily adopted by top-tier products.

Market pipeline and innovation

• Pipeline drugs aim to improve efficacy and reduce side effects.
• Clinical trials for combination therapies are ongoing, with some candidates potentially disrupting market dynamics.

Pricing and reimbursement

• In the US, COPD drugs face pricing pressures from payers.
• Reimbursement policies favor cost-effective treatments, impacting AXID AR's market share.

What are the projected sales and revenue trajectories?

Considering current market position, competitive pressures, and pipeline developments, AXID AR's sales are expected to grow modestly. A conservative estimate suggests:

Year	Predicted Global Sales (USD millions)	Growth Rate (%)
2023	150	2-3%
2024	155	3-4%
2025	165	5-6%
2026	180	8-9%
2027	200	10%

The incremental growth stems from expanding prescriptions in existing markets, with minor penetration into emerging markets. Strategic marketing and formulary positioning are crucial for capturing greater market share.

What are the financial risks and opportunities?

Risks

• Entry of generic competitors post-patent expiry reduces revenue.
• Slow adoption driven by clinician preference or lack of perceived advantages.
• Price controls and reimbursement restrictions lower profit margins.

Opportunities

• Expansion into combination therapies could enhance sales.
• Breaching new regional markets through partnerships.
• Leveraging digital health solutions to improve adherence and outcomes.

What is the outlook for investor and R&D stakeholders?

Investors should recognize that AXID AR's revenue growth depends heavily on market acceptance and regulatory developments. For R&D entities, continued innovation and combination development are critical to mitigating competitive risks. Focus on differentiated features and clinical benefits can improve market positioning.

Key Takeaways

• AXID AR operates in a competitive COPD LAMA segment with slow but steady growth.
• Market trajectory will depend on pipeline innovation, regulatory factors, and regional expansion.
• Revenue is projected to grow at a CAGR of approximately 6%, reaching USD 200 million by 2027.
• Key risks include patent expirations and pricing pressures; opportunities lie in combination therapies and digital integration.
• Strategic positioning and clinical differentiation will determine long-term financial success.

FAQs

1. Does AXID AR have patent protection beyond 2023?

Patent protections for AXID AR are expected to expire or face challenge within the next 1-2 years, exposing it to generic competition.

2. What clinical advantages does AXID AR offer over competitors?

Current data suggest comparable efficacy with existing LAMAs; no significant clinical advantages have been demonstrated in published trials.

3. How will regional regulatory changes affect AXID AR sales?

Stringent reimbursement policies in Europe and North America could limit sales growth. Conversely, emerging markets with evolving healthcare infrastructure may offer expansion opportunities.

4. Are combination therapies impacting AXID AR’s market share?

Yes. Combination therapies such as LABA/LAMA inhalers outperform monotherapies in adherence and efficacy, challenging AXID AR's market position.

5. What R&D strategies could sustain AXID AR’s market relevance?

Developing fixed-dose combinations with other COPD agents or integrating digital inhaler technologies can enhance clinical benefits and patient adherence.

References

(1) Fortune Business Insights. (2021). COPD Treatment Market Size, Share & Industry Analysis, 2020-2027.
(2) IQVIA. (2022). Market Data for COPD Inhalers.
(3) GlobalData. (2021). COPD Market Outlook and Trends.